ALK+ International
@ALKpositiveINT
Followers
1K
Following
6K
Media
272
Statuses
2K
Charity focused on funding & advocating for #research to improve the life expectancy of ALK+ #CancerPatients. #TogetherWeCan further ALK+ cancer research
United Kingdom
Joined March 2022
New @US_FDA approval for #ros1 #lungcancer #taletrectinib based on TRUST-II looks promising clinical data and great to have more drugs in this area @LungCancer_Bio @LungAssociation @OncoAlert @ros1cancer @ros1dersuk @ALKpositiveINT @ALKPositiveinc
https://t.co/Nrz0mZUOy0
fda.gov
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.).
0
2
7
ALK+ International is proud to introduce it's new weekly lottery! 🎰 @ALKpositiveINT receives 40% of ticket price regardless of winner status so why not give it a try today and be in to win up to £25,000! 💸👛💸 https://t.co/4JvIz3sJXe
#Action4Alk
#TogetherWeCan
0
0
1
ALK+ International needs you to invest in hope today and donate to vital medical research into ALK+ cancer. Like, share and follow us across all social media platforms to show your support 💙🩵🩷 Whatever you do, big or small makes a difference, join us and take #ACTION4ALK
0
1
3
ALK+ International are now signed up to Recycle4charity! ♻️🦑 Recycle4Charity is a free programme for empty ink cartridges!- help the environment whilst raising money for much-needed research into ALK+ cancer! Donations of up to £2 per ink cartridge https://t.co/cgUdD6J1Cn
0
0
0
MARIPOSA shows a 25% OS benefit for amivantamab + lazertinib vs osimertinib in newly diagnosed EGFR+ advanced #lungcancer. A big moment—but not a simple one. Side effects, IV treatment & QoL all matter. And right now, this option isn’t available for those in our UK EGFR+
0
14
38
A Journey of Hope: Norman Ng’s Inspiring Story In this episode of OncoInfluencers, @JArakelyan28092 interviews lung cancer survivor Norman Ng, who shares his journey with stage 4 lung cancer, his advocacy work, and his efforts in advancing ALK inhibitors in Hong Kong while
0
2
18
@weldeiry One of my first papers now cited >100x was on EML4-ALK published in Cancer Biology and Therapy as cover image/story thanks to you @weldeiry
https://t.co/llDXHoIBci
@BobTimmermanMD
@IyengarPuneeth
@UTSW_RadOnc
@MDAndersonNews
tandfonline.com
Advanced non-small lung cancer (NSCLC) remains almost uniformly lethal with marginal long-term survival despite efforts to target specific oncogenic addiction pathways that may drive these tumors w...
2
3
9
Dr. Edward Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib. #NSCLC
https://t.co/3C3DzK0MdI
cancernetwork.com
Dr. Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib.
0
2
1
@HHorinouchi @NatureRevCancer @OncoAlert @ALKPositiveinc The review's deep dive into ALK's oncogenic role and emerging resistance to inhibitors is a call to action for innovative cancer therapies. As a cardiologist, I champion the need for sustained research investment, crucial for advancing patient care amidst the UK's challenging
0
1
2
Ultra-deep sequencing of high-risk neuroblastomas found oncogenic aberrations are more prevalent at diagnosis than once thought. ALK and RAS pathway aberrations confer inferior outcomes, emphasizing the need for novel therapeutic approaches.
ascopost.com
A recent study identified the spectrum and clinical significance of clonal and subclonal pathogenic alterations in high-risk neuroblastoma.
0
2
1
ALK+ International is looking for Volunteers! Passionate about ALK+ cancer research? Social media experience? Want to get involved with advocacy? If you believe that research saves lives come and join our team and help us further ALK+ cancer research. #Action4Alk
#TogetherWeCan
0
0
0
Cascade-responsive nano-PROTACs for tumor-specific ALK protein degradation and enhanced cancer therapy https://t.co/IdzZJ8WcHx
0
1
1
Now Dr. @jennifermarksmd presenting Biomarker Testing 101 for Lung Cancer at our Targeted Therapies in Lung Cancer. What is a #biomarker? #ALk #ROS1 #LungCancer #TargetedTherapies #cancerGRACE #CancerEducation
0
1
3
Dr. @DrKarenYunMD presenting: How Do You Read a Molecular Testing Report? What are Driver Alterations in Lung Cancer? #TargetedTherapiesInLungCancer #LungCancer #ALK #ROS1 #RET #NTRK #EGFR #BRAF #MET #HER2 #KRAS
0
2
5
We at @cancerGRACE are fortunate to have @ChristineBestv1 from @UCCancerCenter speaking on ALK, ROS1, and RET at our Targeted Therapies forum. She has become deservedly recognized for her thoughtful commentary in many areas of lung cancer. Many options to consider here.
0
5
29
ALK-EML4 fusion in small cell lung cancer: Clinical and molecular insights from a rare case - Lung Cancer @LungCaJournal
0
1
5
🎙 NEW PODCAST EPISODE! The Riddle Of Drug Response. Today, we speak with Dr. Zachary Rogers, a post-doctoral researcher at MIT’s Koch Institute, whose work on ALK mutations illuminates these advancements. Listen: https://t.co/hH3d3s6qX0 & on all podcast platforms! #Lilly #Bayer
0
1
0
You can also donate straight into our bank account, find the details here: https://t.co/VSlrxvWQrY Donate here: https://t.co/lU8iN6WzT5 Check out our LCAM campaign here:Â https://t.co/fy1bM7uwy2
#Action4Alk
#LungCancerAwarenessMonth #TogetherWeCan further ALK+research
alkinternational.org
Support Us Donations and fundraising are vital to help us work towards our mission of furthering ALK+ cancer research. To read about why research is needed, please see the Research page.
0
0
1